📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: BioLamina

1.1 - Company Overview

BioLamina Logo

BioLamina

Headquarter: Sweden
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of cell culture matrices based on human recombinant laminins for primary cells and stem cell applications. Products include Biolaminin 521 LN and 521 MX for chemically defined, feeder-free self-renewal of human ES/iPS cells (LN: animal origin-free; MX: animal origin-free to the secondary level); 521 CTG for clinical studies and feeder-free culture of PSCs, MSCs, and progenitor cells; 111/121 LN as general attachment proteins; and 211 LN for tissue-specific cell growth and differentiation.

Products and services

  • Biolaminin 521 CTG: Human recombinant laminin 521 substrate, clinical-study-designed, enabling feeder-free culture with an optimal environment for human PSCs, MSCs, and most anchorage-dependent progenitor cell types
  • Biolaminin 521 LN: Human recombinant laminin 521, chemically defined, supporting self-renewal of human ES and iPS cells in an animal origin-free, feeder-free stem cell culture system
  • Biolaminin 521 MX: Human recombinant laminin 521, animal origin-free to the secondary level, maintaining self-renewal of human ES and iPS cells in a chemically defined, feeder-free culture system

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to BioLamina

Scribe Therapeutics Logo

Scribe Therapeutics

HQ: United States Website
  • Description: Provider of CRISPR-based therapeutic platforms and medicines, including X-Editing (XE) technologies for high-activity, specific, deliverable gene editing; CRISPR by Design optimization; ELXR CasX-based epigenetic repressors; in vivo CRISPR genetic medicines (e.g., for sickle cell) with non-viral delivery; and ex vivo natural killer (NK) cell therapies for cancer in collaboration with Sanofi.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Scribe Therapeutics company profile →
GenoSpace Logo

GenoSpace

HQ: United States Website
  • Description: Provider of a precision medicine software platform that makes biomedical data useful and usable, enabling interpretation, analysis, reporting, and collaboration. Offers clinical trial matching using clinical-genomic data, EMR-to-EDC integration to transfer EMR data to clinical trial databases, and study feasibility and site selection tools evaluating enrollment potential and competing trials.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full GenoSpace company profile →
Scipher Medicine Logo

Scipher Medicine

HQ: United States Website
  • Description: Provider of a healthcare platform to determine which drug will work best for each patient, offering PrismRA, a blood test that predicts non-response to TNF inhibitors in rheumatoid arthritis; Spectra, a platform that discovers novel drug targets by analyzing patient molecular data and the human interactome; and PrismUC, a diagnostic test for ulcerative colitis utilizing molecular data to guide treatment decisions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Scipher Medicine company profile →
TissueGene Logo

TissueGene

HQ: United States Website
  • Description: Provider of regenerative biopharmaceutical therapies for orthopedic disorders, offering TG-C, an allogeneic cell and gene therapy designed to treat knee osteoarthritis by reducing pain, improving function, and slowing disease progression.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full TissueGene company profile →
Epistem Logo

Epistem

HQ: United Kingdom Website
  • Description: Provider of specialist contract research services supporting drug discovery and development, offering preclinical in vitro/in vivo models in oncology, inflammatory and gastrointestinal diseases (incl. GI toxicities); GCLP-accredited clinical trial support (histology, IHC, image analysis, gene expression, DNA genotyping); organoid models; cancer stem cell sphere assays; subcutaneous xenografts; orthotopic/metastatic bioluminescent models.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Epistem company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for BioLamina

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to BioLamina

2.2 - Growth funds investing in similar companies to BioLamina

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for BioLamina

4.2 - Public trading comparable groups for BioLamina

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to BioLamina

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About BioLamina

What does BioLamina do?

BioLamina is a provider of cell culture matrices based on human recombinant laminins for primary cells and stem cell applications. Products include Biolaminin 521 LN and 521 MX for chemically defined, feeder-free self-renewal of human ES/iPS cells (LN: animal origin-free; MX: animal origin-free to the secondary level); 521 CTG for clinical studies and feeder-free culture of PSCs, MSCs, and progenitor cells; 111/121 LN as general attachment proteins; and 211 LN for tissue-specific cell growth and differentiation.

Who are BioLamina's competitors?

BioLamina's competitors and similar companies include Scribe Therapeutics, GenoSpace, Scipher Medicine, TissueGene, and Epistem.

Where is BioLamina headquartered?

BioLamina is headquartered in Sweden.

How many employees does BioLamina have?

BioLamina has 1,000 employees 🔒.

When was BioLamina founded?

BioLamina was founded in 2010 🔒.

What sector and industry vertical is BioLamina in?

BioLamina is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for BioLamina

Who are the top strategic acquirers in BioLamina's sector and industry

Top strategic M&A buyers and acquirers in BioLamina's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for BioLamina?

Top strategic M&A buyers groups and sectors for BioLamina include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in BioLamina's sector and industry vertical

Which are the top PE firms investing in BioLamina's sector and industry vertical?

Top PE firms investing in BioLamina's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in BioLamina's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in BioLamina's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in BioLamina's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to BioLamina include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in BioLamina's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for BioLamina?

The key public trading comparables and valuation benchmarks for BioLamina include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for BioLamina for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for BioLamina with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in BioLamina's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for BioLamina with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in BioLamina's' sector and industry vertical?

Access recent funding rounds and capital raises in BioLamina's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for BioLamina